Development and validation of stability indication RP-HPLC method for estimation of satranidazole from its formulation (Record no. 7758)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20210218104223.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 181204b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 6535 |
| Author | Shirode, A. R. |
| 245 ## - TITLE STATEMENT | |
| Title | Development and validation of stability indication RP-HPLC method for estimation of satranidazole from its formulation |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol. 55 (10) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mumbai |
| Year | 2018 |
| Name of publisher, distributor, etc. | Indian Drug Manufacture's Association - IDMA |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 40-48 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | A sensitive stability-indicating high performance liquid chromatography (HPLC) method was developed and validated for quantitative estimation of satranidazole (SAT), a new nitroimidazole with potent antiamoebic activity and accessible in market as tablet and dry syrup either alone or in combination with ofloxacin. The present study involves the development of simple, accurate, precise, reproducible reversed phase high performance liquid chromatography (RP-HPLC) method for determination of satranidazole from its formulation. Isocratic elution at a flow rate of 1.0 mL/min was employed on Hemochrom Intsil C-18 (250 mm× 4.6 mm, 5 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4639 |
| Topical term or geographic name entry element | PHARMACEUTICS |
| 653 ## - Keywords | |
| Keywords | HPLC |
| -- | Satranidazole |
| -- | Marketed dosage form |
| -- | Stability studies |
| -- | ICH |
| -- | Forced degradations |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 6538 |
| Co-Author | Dhumal, A. P. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 6540 |
| Co-Author | Kadam, V. J. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | School of Pharmacy | School of Pharmacy | Archieval Section | 28/03/2019 | 2018006 | 19/06/2019 | 28/03/2019 | Articles Abstract Database |